These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31606227)

  • 1. A model-based patient selection tool to identify who may be at risk of exceeding dose tolerances during pancreatic SBRT.
    Magallon-Baro A; Granton PV; Milder MTW; Loi M; Zolnay AG; Nuyttens JJ; Hoogeman MS
    Radiother Oncol; 2019 Dec; 141():116-122. PubMed ID: 31606227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic cancer treated with SBRT: Effect of anatomical interfraction variations on dose to organs at risk.
    Loi M; Magallon-Baro A; Suker M; van Eijck C; Sharma A; Hoogeman M; Nuyttens J
    Radiother Oncol; 2019 May; 134():67-73. PubMed ID: 31005226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Daily Online Plan Adaptation Strategies for a Cohort of Pancreatic Cancer Patients Treated with SBRT.
    Magallon-Baro A; Milder MTW; Granton PV; Nuyttens JJ; Hoogeman MS
    Int J Radiat Oncol Biol Phys; 2021 Sep; 111(1):208-219. PubMed ID: 33811976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simulated Online Adaptive Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Oligometastatic Disease of the Abdomen and Central Thorax: Characterization of Potential Advantages.
    Henke L; Kashani R; Yang D; Zhao T; Green O; Olsen L; Rodriguez V; Wooten HO; Li HH; Hu Y; Bradley J; Robinson C; Parikh P; Michalski J; Mutic S; Olsen JR
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1078-1086. PubMed ID: 27742541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simulated computed tomography-guided stereotactic adaptive radiotherapy (CT-STAR) for the treatment of locally advanced pancreatic cancer.
    Schiff JP; Price AT; Stowe HB; Laugeman E; Chin RI; Hatscher C; Pryser E; Cai B; Hugo GD; Kim H; Badiyan SN; Robinson CG; Henke LE
    Radiother Oncol; 2022 Oct; 175():144-151. PubMed ID: 36063981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling daily changes in organ-at-risk anatomy in a cohort of pancreatic cancer patients.
    Magallon-Baro A; Loi M; Milder MTW; Granton PV; Zolnay AG; Nuyttens JJ; Hoogeman MS
    Radiother Oncol; 2019 May; 134():127-134. PubMed ID: 31005206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic body radiation therapy for liver tumors: impact of daily setup corrections and day-to-day anatomic variations on dose in target and organs at risk.
    Méndez Romero A; Zinkstok RT; Wunderink W; van Os RM; Joosten H; Seppenwoolde Y; Nowak PJ; Brandwijk RP; Verhoef C; IJzermans JN; Levendag PC; Heijmen BJ
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1201-8. PubMed ID: 19386435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization and management of interfractional anatomic changes for pancreatic cancer radiotherapy.
    Liu F; Erickson B; Peng C; Li XA
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e423-9. PubMed ID: 22436785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linac-based stereotactic body radiation therapy for unresectable locally advanced pancreatic cancer: risk-adapted dose prescription and image-guided delivery.
    Mazzola R; Fersino S; Aiello D; Gregucci F; Tebano U; Corradini S; Di Paola G; Cirillo M; Tondulli L; Ruffo G; Ruggieri R; Alongi F
    Strahlenther Onkol; 2018 Sep; 194(9):835-842. PubMed ID: 29696321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosimetric Benefits and Practical Pitfalls of Daily Online Adaptive MRI-Guided Stereotactic Radiation Therapy for Pancreatic Cancer.
    El-Bared N; Portelance L; Spieler BO; Kwon D; Padgett KR; Brown KM; Mellon EA
    Pract Radiat Oncol; 2019 Jan; 9(1):e46-e54. PubMed ID: 30149192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose Prediction Model for Duodenum Sparing With a Biodegradable Hydrogel Spacer for Pancreatic Cancer Radiation Therapy.
    Feng Z; Rao AD; Cheng Z; Shin EJ; Moore J; Su L; Kim SH; Wong J; Narang A; Herman JM; McNutt T; Li D; Ding K
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(3):651-659. PubMed ID: 30031143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The first reported case of a patient with pancreatic cancer treated with cone beam computed tomography-guided stereotactic adaptive radiotherapy (CT-STAR).
    Kim M; Schiff JP; Price A; Laugeman E; Samson PP; Kim H; Badiyan SN; Henke LE
    Radiat Oncol; 2022 Sep; 17(1):157. PubMed ID: 36100866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of interfraction dose variation in pancreas SBRT using daily simulation MR images.
    Young T; Lee M; Johnston M; Nguyen T; Ko R; Arumugam S
    Phys Eng Sci Med; 2023 Dec; 46(4):1619-1627. PubMed ID: 37747645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Silico Trial of Computed Tomography-Guided Stereotactic Adaptive Radiation Therapy (CT-STAR) for the Treatment of Abdominal Oligometastases.
    Schiff JP; Stowe HB; Price A; Laugeman E; Hatscher C; Hugo GD; Badiyan SN; Kim H; Robinson CG; Henke LE
    Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):1022-1031. PubMed ID: 35768023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
    Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
    J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of patients with locally advanced pancreatic cancer benefitting from plan adaptation in MR-guided radiation therapy.
    Bohoudi O; Bruynzeel AME; Meijerink MR; Senan S; Slotman BJ; Palacios MA; Lagerwaard FJ
    Radiother Oncol; 2019 Mar; 132():16-22. PubMed ID: 30825964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer.
    Bohoudi O; Bruynzeel AME; Senan S; Cuijpers JP; Slotman BJ; Lagerwaard FJ; Palacios MA
    Radiother Oncol; 2017 Dec; 125(3):439-444. PubMed ID: 28811038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential dosimetric benefits of adaptive tumor tracking over the internal target volume concept for stereotactic body radiation therapy of pancreatic cancer.
    Karava K; Ehrbar S; Riesterer O; Roesch J; Glatz S; Klöck S; Guckenberger M; Tanadini-Lang S
    Radiat Oncol; 2017 Nov; 12(1):175. PubMed ID: 29121945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting dose-volume histograms for organs-at-risk in IMRT planning.
    Appenzoller LM; Michalski JM; Thorstad WL; Mutic S; Moore KL
    Med Phys; 2012 Dec; 39(12):7446-61. PubMed ID: 23231294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosimetric impact of different CT datasets for stereotactic treatment planning using 3D conformal radiotherapy or volumetric modulated arc therapy.
    Oechsner M; Odersky L; Berndt J; Combs SE; Wilkens JJ; Duma MN
    Radiat Oncol; 2015 Dec; 10():249. PubMed ID: 26626865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.